Title:
PHARMACEUTICAL FOR TREATING AND/OR PREVENTING CANCER
Document Type and Number:
WIPO Patent Application WO/2024/043252
Kind Code:
A1
Abstract:
This pharmaceutical containing, collectively or separately as a combination, an antibody having immunological reactivity with respect to CAPRIN-1 protein or a fragment of said antibody, and an epidermal growth factor receptor (EGFR) inhibitor, is useful for treating and/or preventing cancer.
Inventors:
WASAI UKEI (JP)
OKANO FUMIYOSHI (JP)
SAITO TAKANORI (JP)
OKANO FUMIYOSHI (JP)
SAITO TAKANORI (JP)
Application Number:
PCT/JP2023/030225
Publication Date:
February 29, 2024
Filing Date:
August 23, 2023
Export Citation:
Assignee:
TORAY INDUSTRIES (JP)
International Classes:
A61K39/395; A61K31/517; A61K31/519; A61K45/00; A61P35/00; A61P35/02; A61P43/00; C07K16/28
Domestic Patent References:
| WO2021182573A1 | 2021-09-16 |
Other References:
山田 一彦, 多標的分子標的治療薬, 日本臨牀, 2009, vol. 67, extra edition 1 (Pharmacotherapeutics of Cancer), pp. 301-305, ISSN 0047-1852
NISHIOKA, YASUHIKO, SONE, SABURO: "Molecularly targeted therapeutic drugs that target multiple molecules", HISTORY OF MEDICINE, vol. 224, no. 13, 1 January 2008 (2008-01-01), JP , pages 1114 - 1117, XP009552943, ISSN: 0039-2359
小寺 康夫, 多標的チロシンキナーゼ阻害剤の種類と特徴, Mebio. 2009, vol. 26, no. 5, pp. 74-83, ISSN 0910-0474
HIBIKI UDAGAWA, SHINICHI HASAKO, AKIHIRO OHASHI, RUMI FUJIOKA, YUMI HAKOZAKI, MIKIKO SHIBUYA, NAOMI ABE, TOSHIHARU KOMORI, TOMONOR: "TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations", MOLECULAR CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 17, no. 11, 1 November 2019 (2019-11-01), US , pages 2233 - 2243, XP055690448, ISSN: 1541-7786, DOI: 10.1158/1541-7786.MCR-19-0419
FRY D W ET AL: "Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 95, no. 20, 29 September 1998 (1998-09-29), pages 12022 - 12027, XP002246246, ISSN: 0027-8424, DOI: 10.1073/pnas.95.20.12022
NISHIOKA, YASUHIKO, SONE, SABURO: "Molecularly targeted therapeutic drugs that target multiple molecules", HISTORY OF MEDICINE, vol. 224, no. 13, 1 January 2008 (2008-01-01), JP , pages 1114 - 1117, XP009552943, ISSN: 0039-2359
小寺 康夫, 多標的チロシンキナーゼ阻害剤の種類と特徴, Mebio. 2009, vol. 26, no. 5, pp. 74-83, ISSN 0910-0474
HIBIKI UDAGAWA, SHINICHI HASAKO, AKIHIRO OHASHI, RUMI FUJIOKA, YUMI HAKOZAKI, MIKIKO SHIBUYA, NAOMI ABE, TOSHIHARU KOMORI, TOMONOR: "TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations", MOLECULAR CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 17, no. 11, 1 November 2019 (2019-11-01), US , pages 2233 - 2243, XP055690448, ISSN: 1541-7786, DOI: 10.1158/1541-7786.MCR-19-0419
FRY D W ET AL: "Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 95, no. 20, 29 September 1998 (1998-09-29), pages 12022 - 12027, XP002246246, ISSN: 0027-8424, DOI: 10.1073/pnas.95.20.12022
Download PDF:
Previous Patent: METHOD FOR PREDICTING CELL MEMBRANE PERMEABILITY OF CYCLIC PEPTIDE
Next Patent: POWER STORAGE DEVICE
Next Patent: POWER STORAGE DEVICE